Sarepta Therapeutics, Inc.
Eteplirsen
Muscular Dystrophy, Duchenne
Countdown
117days
Phase 3 readout · Oct 31, 2026
What's at stake
Phase 3 trial results for Eteplirsen in Muscular Dystrophy, Duchenne are due Oct 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 13h ago
“CT.gov NCT03992430: Phase 3 trial, sponsor Sarepta Therapeutics, Inc., drug Eteplirsen. Primary completion date 2026-10-31 (estimated).”